Paper Details

  1. Home
  2. Paper Details

A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.

Author: CheuvartBrigitte, LeyssenMaarten, MillerJacqueline M, Pankow-CulotHeidemarie, ScheifeleDavid, ThollotFranck, UlianovLiliana

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A phase II, randomized study compared the immunogenicity and safety of a heptavalent combination vaccine with licensed control vaccines in 480 infants. The study found that the heptavalent vaccine induced non-inferior MenC and Hib responses compared to control vaccines. Both vaccination regimens were immunogenic to all antigens but had lower-than-expected responses to poliomyelitis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The immunogenicity and safety of the investigational diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b (Hib) and meningococcal serogroup C (MenC) heptavalent combination vaccine were compared with those of licensed control vaccines. METH...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/INF.0000000000000468

データ提供：米国国立医学図書館（NLM）

Heptavalent Combination Vaccine: A New Oasis in Infant Immunization

Immunization, like a sturdy camel caravan, protects infants from a multitude of diseases. This research investigates the immunogenicity and safety of a new heptavalent combination vaccine for infants, offering a potential oasis of protection against a wider range of diseases. The study compared the heptavalent vaccine with licensed control vaccines, aiming to assess its effectiveness and safety in infants.

A Multi-faceted Oasis: The Heptavalent Vaccine Offers Comprehensive Protection

The research suggests that the heptavalent vaccine, like a well-equipped oasis, offers comprehensive protection against seven diseases, including diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b (Hib), and meningococcal serogroup C (MenC). The study demonstrated non-inferiority of immune responses to MenC and Hib induced by the heptavalent vaccine compared to the control vaccines, highlighting its effectiveness in eliciting robust immune responses.

A Safe and Effective Journey: Ensuring Infant Health and Well-being

This research, like a well-traveled caravan route, demonstrates the safety and efficacy of the heptavalent combination vaccine for infants. The study found no significant differences in safety and reactogenicity profiles between the heptavalent vaccine and control vaccines. This indicates that the heptavalent vaccine offers a safe and effective option for protecting infants against a wider range of diseases.

Dr.Camel's Conclusion

This research is a testament to the ongoing advancements in infant immunization, offering a new oasis of protection against a wider range of diseases. The heptavalent vaccine, with its demonstrated safety and efficacy, provides a valuable tool for ensuring the health and well-being of infants. As a camel who has traversed many a desert landscape, I am optimistic about the potential of this new vaccine to protect our young ones and pave the way for a healthier future.

Date :
  1. Date Completed 2015-06-26
  2. Date Revised 2014-11-12
Further Info :

Pubmed ID

25037033

DOI: Digital Object Identifier

10.1097/INF.0000000000000468

Related Literature

Article Analysis
・Side Effects of pneumococcal conjugate vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.